GlassScriptPhysician profile
Janice Schiff
NPI 1508333816
$3,784.46
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,015 · 2022: $671 · 2023: $1,388 · 2024: $710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,098.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,098.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $879.84 | 2021-2024 | |
| Vanda Pharmaceuticals INC. | $611.94 | 2021-2024 | Fanapt, Hetlioz |
| Corium, LLC | $527.89 | 2022-2024 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $340.83 | 2021-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $316.92 | 2021-2024 | Rexulti, Abilify Mycite, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $292.64 | 2021-2024 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $270.86 | 2021-2024 | Uzedy, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $156.70 | 2021 | |
| Janssen Pharmaceuticals, INC | $121.34 | 2021-2023 | Spravato |
| Alkermes, INC. | $69.60 | 2022-2024 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $51.29 | 2023-2024 | Auvelity |
| Eisai INC. | $46.31 | 2021 | |
| Neurocrine Biosciences, INC. | $35.91 | 2024 | Ingrezza |
| Lundbeck LLC | $22.30 | 2021 | |
| Merck Sharp & Dohme LLC | $20.49 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $19.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janice Schiff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.